Hepatitis B antiviral agents

A compound of Formula (III):

• or a pharmaceutically acceptable salt thereof;
• wherein:
• the substituents —C(═O)N(R6)2 and —C(═O)NR4— are in a 1,3-position with respect to each other;
• ring B is a monocyclic aryl ring;
• R2 and R5 are independently selected at each occurrence from the group consisting of halo, —CN, —NO2, -(L)m-OR8, -(L)m-C(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-CH(R8)2, -(L)m-N(R8)2, -(L)m-C(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 alkyl, and —C1-C6 heteroalkyl;
• R4 is H;
• the R6 groups attached to the same N atom are taken together with the N atom to which they are attached to form an optionally substituted C2-C10 heterocycloalkyl ring, wherein the ring optionally comprises a moiety selected from N—R4, and wherein the heterocycloalkyl ring is optionally substituted with 0-5 substituents selected from R2;
• each RB is independently, at each occurrence, H or C1-C6 alkyl;
• R9 is C1-C6 alkyl or C3-C10 cycloalkyl;
• each occurrence of y is independently selected from the group consisting of 0, 1, 2, 3 and 4;
• each occurrence of x is 0;
• L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)m-, and —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-;
• and
• each occurrence of m is independently 0, 1 or 2.